In the previous study, we demonstrated that the nuclear isoform of T cell protein-tyrosine phosphatase (TC-PTP) dephosphorylated and deactivated signal transducer and activator of transcription 5a (STAT5a) and STAT5b, thereby negatively regulating prolactin (PRL)-mediated signaling pathway. In this study, we examined the involvement of the nuclear isoform of TC-PTP in Interleukin-6 (IL-6)-mediated signaling pathway. IL-6 is a multifunctional cytokine that plays important roles in the immune system, hematopoiesis, and acute phase reactions, and has also implicated in IL-6-related diseases. Here we demonstrate that IL-6-induced tyrosine-phosphorylation and activation of STAT3 were suppressed by overexpression of the nuclear isoform of TC-PTP in 293T cells.
INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates immune and inflammatory responses (1, 2), and also implicated in IL-6-related diseases (2) . The IL-6 receptor is a heterodimeric complex, consisting of an IL-6 specific ligand-binding subunit, α chain, and a signal-transducing subunit, gp130. Structural analysis has revealed that both subunits belong to the cytokine receptor superfamily, and gp130 is shared by the receptors for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and cardiotropin 1(CT-1) (3, 4) . The binding of IL-6 to α chain leads to the formation of receptor complexes, followed by tyrosine phosphorylation and activation of Janus protein tyrosine kinases (Jaks) and various cellular proteins, including gp130 itself. The activated Jaks, in turn, phosphorylate and activate latent signal transducer and activator of transcription (STAT) family of transcription factors (5, 6) .
One member of the STAT family of proteins is STAT3, which is mainly activated by IL-6 family of cytokines, epidermal growth factor, and leptin (3, 4) . Like other members of the STAT family, STAT3 is tyrosine-phosphorylated by Jaks, upon which it dimerizes, and translocates into the nucleus to activate target genes (5, 6) .
Protein-tyrosine phosphatases (PTPs) are a large and structurally diverse family of enzyme that catalyze the dephosphorylation of tyrosine-phosphorylated proteins (7, 8) . PTPs have been shown to participate as either positive or negative regulators of signal transduction in a wide range of physiological processes, which include cellular growth and proliferation, migration, differentiation, and survival (7, 8) . Despite their important roles in a wide range of physiological and pathological processes, the mechanism by which PTPs exert their effects is often poorly understood.
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T cell PTP (TC-PTP) is a ubiquitous intracellular PTP that was cloned originally from a peripheral human T-cell cDNA library (9, 10) . Alternative splicing gives rise to two forms of TC-PTP that differ in the C termini, a 45-kDa isoform that is targeted to the nucleus and a 48-kDa isoform that localizes to the endoplasmic reticulum via a hydrophobic C-terminal region (11, 12, 13) . In a recent study, it was shown that cellular stress causes reversible cytoplasmic accumulation of the 45-kDa isoform of TC-PTP (14) . TC-PTP is found in higher amounts in lymphoid and hematopoietic cell lineages, suggesting that TC-PTP plays an important role in both hematopoiesis and immune function (9 10). Very interestingly, TC-PTP-deficient mice showed impaired bone marrow microenvironment and immune function (15) . Especially, bone marrow of TC-PTP deficient mice failed to support the development of B cells and erythrocytes, but not granulocytes and macrophages.
More recently, we demonstrated that the nuclear isoform of TC-PTP dephosphorylated and deactivated STAT5a and STAT5b in transfected COS-7 cells as well as in mammary epithelial COMMA-1D cells, thereby negatively regulating the PRL-mediated signaling pathway (16) as well as PTP1B (17) which is structurally highly related TC-PTP comprises a subfamily of intracellular PTPs.
In this study, we examined the involvement of the nuclear isoform of TC-PTP in the IL-6-mediated signaling pathway. The data demonstrated that the nuclear isoform of TC-PTP was a potential negative regulator of IL-6-mediated signal transduction by dephosphorylating and deactivating STAT3. Of particular note is that overexpression of the nuclear isoform of TC-PTP was found to suppress the IL-6-induced growth arrest of myeloid leukemia M1 cells and endogenous TC-PTP complexed with STAT3 in the nucleus of M1 cells.
MATERIALS AND METHODS

Reagents and antibodies
Human recombinant IL-6 was a kind gift from Ajinomoto (Tokyo, Japan). Human recombinant soluble IL-6 receptor α (sIL-6Rα) was a kind gift from Dr. Hirano (Osaka Univ., Osaka, Japan). Human recombinant LIF was purchased from INTERGEN (Purchase, NY).
Expression vectors, Jak1, FLAG-tagged STAT3 and STAT3-LUC (18) were kindly provided by Dr. J. N. Ihle (St. Jude CRH., Memphis, TN) and Dr. T. Hirano (Osaka Univ., Osaka, Japan), respectively. Myc-tagged STAT3 mutants were generated by PCR methods and sequenced (primer sequences are available upon request). Anti-HA, anti-Myc, anti-STAT3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-phosphotyrosine (PY20) was purchased from Pharmingen (San Diego, CA).
Anti-FLAG M2 antibody was purchased from Upstate Biotechnology (Lake Placid, NY).
Anti-TC-PTP 3E2 monoclonal antibody was a kind gift from Dr. M. L. Tremblay ( McGill Univ., Montreal, Canada) (15) .
Cell culture, transfections, luciferase assays, and cell growth assays M1, a murine myeloid leukemia cell line was cultured in RPMI 1640 containing 10% fetal calf serum (FCS). Human embryonic kidney carcinoma cell line, 293T was maintained in DMEM containing 10% FCS and transfected by the standard calcium precipitation protocol.
Luciferase assay was performed as described (19) . The cells were harvested and lysed in 100 μl of PicaGene Reporter Lysis Buffer (Toyo Ink, Tokyo, Japan) and assayed for luciferase and β-galactosidase activities according to the manufacturer's instructions. Luciferase activities were normalized to the β-galactosidase activities. Cell growth was determined by Cell Counting Kit-8 (Wako Chemicals, Tokyo, Japan) according to the manufacturer's instructions.
In Vitro Dephosphorylation Assay
GST fusion proteins containing full-length nuclear isoform of TC-PTP was described previously (16) . STAT3 immune complexes prepared from 293T cells that had been transfected with STAT3 together with Jak1 were processed and incubated with indicated GST fusion proteins as previously described (17) .
Retrovirus-mediated gene delivery
HA-tagged nuclear isoform of TC-PTP in pLXSN retroviral vector (16) introduced into
PLATE-E ecotropic packaging cells (20). M1 cells were infected with the retrovirus-containing culture medium and then selected in the presence of G418 (1 mg/ml) for 2 wk. To eliminate clonal deviation, G418-resistant polyclonal cells were used for subsequent experiments.
Immunoprecipitation and immunoblotting
The immunoprecipitation and Western blotting were performed as described previously (21) .
293T cells were harvested and lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 μM phenylmethylsulfonyl fluoride and 10 μg/ml each of aprotinin, pepstatin and leupeptin). M1 cells (2x10 ８ cells) were stimulated with IL-6 (1 μg/ml) for 30 min. Nuclear extracts were prepared as described previously (22) . Nuclear extracts in the 
RESULTS AND DISCUSSION
TC-PTP dephosphorylates and deactivates IL-6-activated STAT3 in 293T cells
In our previous study, we showed that the nuclear isoform of TC-PTP dephosphorylated PRL-activated STAT5a and STAT5b (13) . To examine whether the nuclear isoform of TC-PTP has any effects on IL-6-stimulated STAT3 activation, we first assessed changes in tyrosine-phosphorylation of STAT3, which trigger its activation, in 293T cells. In these experiments, 293T cells were stimulated with IL-6 in the presence of soluble IL-6 receptor α 
STAT3 and TC-PTP physically interact in 293T cells
One of the mechanisms that are consistent with the data described above is direct dephosphoryaltion of STAT3 by the nuclear isoform of TC-PTP, which trigger its deactivation. We first tested this possibility by co-immunoprecipitation experiments. These data suggest that the C-terminal region containing the critical tyrosine phosphorylation site, which is indispensable for its activation, is required for STAT3 to interact with TC-PTP.
STAT3 is a specific substrate of TC-PTP
To further confirm dephosphorylation action of TC-PTP on STAT3, recombinant glutathione-S-transferase (GST) fusion protein containing full-length nuclear isoform of TC-PTP WT was expressed in Escherichia coli and purified as described previously (15) .
293T cells that had been transfected with FLAG-tagged STAT3 together with Jak1, and phosphorylated STAT3 was immunoprecipitated. The indicated amounts of the recombinant GST-TC-PTP WT fusion protein and GST were added to the immune complexes and incubated at 37 ℃ for 30 min. As shown in Fig. 3A , the tyrosine phosphorylation level of STAT3 was reduced to approximately 70% by 3 μg TC-PTP WT, and incubation with 10 μg of the fusion protein resulted in complete dephosphorylation of STAT3 (Fig 3) . Incubation of the immune complexes with empty GST resulted in no reduction in tyrosine phosphorylation level of STAT3, suggesting that STAT3 is a specific substrate of TC-PTP.
TC-PTP suppresses IL-6-induced growth arrest of myeloid leukemia M1cells
To examine the role of TC-PTP in IL-6-mediated signaling under more physiological conditions, TC-PTP was introduced into myeloid leukemia M1cells by a retroviral infection system. Myeloid leukemia M1cells can be induced for growth arrest and terminal differentiation into macrophages in response to IL-6 or LIF (3, 17) . The nuclear isoform of HA-tagged TC-PTP cDNA was ligated into a retroviral vector and introduced into M1cells.
Cells were selected in G418-supplemented cell culture medium and then directly used for subsequent experiments. Similar amounts of HA-tagged TC-PTP and mutants were expressed in M1 cells (Fig. 4A ). The mock-or catalytically inactive TC-PTP-transfected M1cells underwent cell death after treatment with IL-6 for 3 days. However, in the cells expressing TC-PTP WT, IL-6-induced growth arrest was inhibited by 50 % compared with that of mock transfectants (Fig. 4B) . These results strongly suggest that the nuclear isoform of TC-PTP regulates IL-6 signaling pathway in M1 cells.
To further confirm that endogenous TC-PTP interact with STAT3 in vivo, co-immunoprecipitation experiments were performed using nuclear extracts obtained from untransfected M1 cells that were either left untreated or were treated with IL-6. As shown in Recent studies identified several molecules that regulate IL-6 signaling. Suppressors of cytokine signaling (SOCS-1), which is induced by various cytokines including IL-6, suppresses Jak-STAT signaling by direct interaction with Jak kinases (25, 26, 27) . Protein inhibitor of activated STAT3 (PIAS3) inhibits DNA binding activity of activated Stat3 and subsequent gene expression (28) . Several PTPs are shown to play an important role in the regulation of IL-6 signaling pathway. However, no nuclear protein tyrosine phosphatase has been shown to involve in the regulation of IL-6 signaling pathway. Src homology 13 2-containing phosphatase 2 (SHP-2) involved in the down regulation of Jak-STAT signaling activated by several cytokines (29, 30, 31) . Furthermore, upon IL-6 stimulation, SHP-2 also acted as an adaptor associating with Grb2 and activated mitogen-activated protein kinase (MAPK) (29, 32) . A cytosolic isoform of PTPε, PTPεC, is also shown to reveal an inhibitory effect on STAT3 activation induced by IL-10 as well as by 34) . We demonstrated that a classical PTP, PTP1B negatively regulated the PRL-mediated signaling pathway by dephosphorylating and deactivation of STAT5a and STAT5b in mammary epithelial cells as well as the nuclear isoform of TC-PTP (15, 16) . Jak2 and Tyk2, but not Jak1 were also demonstrated to be substrates of PTP1B (36) . PTP1B is well known to be responsible for negatively regulating insulin signaling by dephosphorylating the phosphotyrosine residues of the insulin receptor kinase (37, 38) . PTP1B knockout study identified PTP1B as a promising target for anti-diabetes/obesity drug discovery (39) . Recently, TC-PTP deficient mice were developed (18) . The phenotype of TC-PTP deficient mice was not lethal in utero, but all 293T cells (1x10 7 ) were transfected with FLAG-tagged STAT3 (7.5μg), together with Jak1(1 μg). 48 h after transfection, cells were and then subjected to an in vitro dephosphorylation assay as described in MATERIALS AND METHODS. After termination of the incubation, proteins were separated by SDS-PAGE and analyzed with an anti-phosphotyrosine antibody (PY). The same blot was reprobed with anti-FLAG antibody after stripping. 
